All News

All News

Targeted Treatment of Follicular Lymphoma

Recent advances in understanding of the unique genetic and immune biology of FL have led to increasingly potent and precise novel targeted agents, suggesting that a CT-future...

Melphalan Flufenamide Receives Accelerated Approval for Relapsed/Refractory Multiple Myeloma

Melphalan flufenamide, in combination with dexamethasone, has received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory MM who have received...

ASH Clinical News
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer

The multicenter VARIANZ study aims to investigate the background of response and resistance to trastuzumab in mGC.

Journal of Clinical Oncology

source list reference


Content Feed

Final Results From the International Tailored Chemotherapy Adjuvant Trial

Findings from a Phase III study found that evaluating mRNA expression of selected genes to tailor adjuvant chemotherapy did not improve survival outcomes among patients with resected stage II-III N

Oncology Times - Latest Articles
Diet and Exercise Intervention May Increase Efficacy of Chemotherapy in Pediatric Patients With Leukemia

Research published by Orgel et al shows that restricting calories, reducing fat and sugar intake, and increasing physical activity may boost the effectiveness of chemotherapy for older children and

The ASCO Post
New ASH Guidelines: VTE Prevention and Treatment in Cancer Patients

New ASH guidelines "strongly recommend" using no thromboprophylaxis over using parenteral thromboprophylaxis in ambulatory patients receiving cancer CT who have low VTE risk.

Seminal Vesicle-Sparing in Radical Cystectomy Shown to Improve Outcomes

Seminal vesicle sparing at radical cystectomy provides good oncologic outcomes and helps to preserve urinary continence and sexual function in well-selected patients with bladder cancer, a new stud

Cancer Therapy Advisor
CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma

Lisocabtagene maraleucel is a CAR-T therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.

JAMA Network
NCCN Issues Guidance on COVID-19 Vaccination for Patients With Cancer

Oncology groups including ASCO, ASH, and the American Society for Radiation Oncology have all recommended patients with cancer get vaccinated. Now the NCCN has published a similar guidance.

Oncology Times - Latest Articles
Ivosidenib or Enasidenib Combined With Intensive Chemotherapy in Patients With Newly Diagnosed AML

Ivosidenib or enasidenib combined with induction and consolidation chemotherapy were both well tolerated in newly diagnosed mIDH1/2 AML.

Correlation Between Family History and Characteristics of Breast Cancer

Herein, study investigators researched the link between family history and breast cancer features to elucidate the importance of family history in the diagnosis and treatment of breast cancer. 

Scientific Reports
CARs Are the Ride of the Future for Curing DLBCL

Chimeric antigen receptor T-cell therapy has the potential to cure the most diffuse large B-cell lymphoma patients who have recurrent disease.

Oncology Times - Latest Articles
First CAR T-Cell Therapy for Multiple Myeloma: Abecma

CAR T-cell therapy, described as a "living drug," is now available for patients with relapsed/refractory multiple myeloma who have been treated with four or more prior lines of therapy.

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Study investigators conduct a phase I trial of autologous CD19.28ζ-CAR T cells in CAYAs with relapsed or refractory B-ALL.

Journal of Clinical Oncology
‘On-Your-Toes’ Approach to Managing Infection Risk Needed as CAR T-Cell Therapy Evolves

Chimeric antigen receptor T-cell therapy employs a patient’s immune system to fight cancer and thereby weakens it, leaving the recipient vulnerable to infection.

Outpatient CAR T-Cell Therapy Safe, Effective for Advanced Large B-Cell Lymphoma

Patients with relapsed or refractory large B-cell lymphoma who received lisocabtagene maraleucel had similar response rates regardless of the type of center providing the CAR T-cell therapy.

CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma

Lisocabtagene maraleucel, marketed as Breyanzi, is a CAR-T therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.

JAMA Network
Tear Lipid Metabolites As Potential Diagnostic Biomarkers for Ocular Chronic Graft-Versus-Host Disease

cGVHD remains a common threat after allo-HSCT, and ocular manifestations occur in up to 60% to 90% of cGVHD patients.

Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy

This retrospective analysis includes patients ≥60 years of age with AML who received an alloHCT after treatment with decitabine or intensive chemotherapy. 

CAR T-Cell Therapy: Current Practice and Future Solutions to Optimize Patient Access

This review article will address these clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.

Journal of Clinical Pathways
Ultrasound and Bioptic Investigation of Patients With Primary Sjögren’s Syndrome

Authors summarize the role of different imaging techniques and a bioptic approach in pSS patients, focusing mainly on the role of salivary gland ultrasonography and a US-guided core needle biopsy a

Journal of Clinical Medicine
Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant

This review examines the diagnostic criteria and clinical characteristics of HCL-v and presents a comprehensive overview of current therapeutic options in HCL-v.

OncoTargets and Therapy
Targeting Bruton Tyrosine Kinase Using Non-covalent Inhibitors in B Cell Malignancies

This review discusses the rationale for the use of non-covalent BTK inhibitors and the preclinical and clinical studies of non-covalent BTK inhibitors in B cell malignancies.

Journal of Hematology & Oncology
Vitamin D for All Over 50s to Prevent Cancer Deaths?

The recent data come from three meta-analyses published in 2019 that show a consistent and significant 13% reduction in cancer mortality with vitamin D.

Clinical Sequencing to Assess Tumor Mutational Burden as a Useful Biomarker to Immunotherapy in Various Solid Tumors

Tumor mutational burden has been considered as a useful marker to indicate patients who benefit from ICIs.

Therapeutic Advances in Medical Oncology
LuPSMA Outperforms Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer in Phase II Trial

Following disease progression on docetaxel, PSMA-targeted radionuclide therapy reduces the risk of disease progression or death by 37% vs cabazitaxel in men with mCRPC...

The ASCO Post
Germline BRCA1/2 and Other Predisposition Genes in Patients With Metastatic Breast Cancer: Prevalence and Association With Prognosis

Fasching and colleagues identify the prevalence of germline mutations in BRCA1/2 and other breast cancer risk genes in patients with metastatic disease and found similar prognosis with pre

The ASCO Post
Overall Survival With Olaparib vs Placebo Maintenance in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and BRCA1/2 Mutation

The phase III SOLO2/ENGOT-Ov21 trial has shown a large numeric but statistically nonsignificant improvement in the secondary endpoint of overall survival with olaparib tablet maintenance therapy vs

The ASCO Post
Inhibitory Effects of Periplocin on Lymphoma Cells: A Network Pharmacology Approach and Experimental Validation

The effects of periplocin on lymphoma and the underlying mechanisms of action remain unclear.

Drug Design, Development and Therapy
The Imbalance of Circulating Follicular T Helper Cell Subsets in Primary Sjögren’s Syndrome Associates With Serological Alterations and Abnormal B-Cell Distribution

This study investigates whether a change in the balance of circulating TFH subsets and follicular regulatory T cells could affect the distribution of B cells in pSS. 

Frontiers in Immunology
Karonudib Has Potent Anti-Tumor Effects in Preclinical Models of B-Cell Lymphoma

Study investigators test the efficacy of karonudib in vitro and in preclinical B-cell lymphoma models. 

Scientific Reports
What Are The Symptoms of NSCLC?


The symptoms of non-small cell lung cancer are not specific. Learn more here about the possible symptoms. 

Radiosurgery Followed by Tumor-Treating Fields for NSCLC Brain Metastases

Dr Minesh P Mehta discusses radiosurgery followed by tumor-treating fields for NSCLC brain metastases.

Motivating Stage III NSCLC Patients to Stay on Treatment

Oncology specialists from a lung multidisciplinary team discuss best practices on motivating patients to stay on therapy.

Expert Video Report on Lung Cancer From ASCO 2020

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Egbert Smit comments on important and potentially practice changing study results in NSCLC.

CARs Are the Ride of the Future for Curing DLBCL

CAR T-cell therapy has the potential to cure the most diffuse large B-cell lymphoma patients who have recurrent disease.

Oncology Times - Latest Articles
Relugolix As First Oral GnRH Antagonist Option for Prostate Cancer

The FDA recently approved relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, for adults with advanced prostate cancer. 

Oncology Times - Latest Articles
New Database of HPV-Negative Head & Neck Carcinomas Unveiled

New research clarifies the contributions of genes, proteins, and signaling pathways associated with HPV-negative head and neck squamous cell carcinomas.

Oncology Times - Latest Articles
Significance of EZH2 Expression in Endometrial Cancer

To identify new targets, researchers have explored the relevance of epigenetic modifiers in cancer therapeutics. One such potential candidate is enhancer of zeste homolog 2 (EZH2). 

Oncology Times - Latest Articles
Tipifarnib for Patients With Advanced HRAS-Mutant Head and Neck Cancer and High Variant Allele Frequency

In a phase II trial, Ho et al finds that tipifarnib produces a high response rate among patients with recurrent or metastatic HNSCC with HRAS mutations and high variant allele frequency.

The ASCO Post
Liver Transplant Emerges for Hepatic Mets in Colorectal Cancer

Liver transplant might be the next big thing for extensive hepatic metastases in colorectal cancer.

Standardization & Harmonization of Immuno-Oncology Toxicities

A report from the Association of Community Cancer Centers shows that IO treatment is increasingly being given to patients in community settings, not just in academic cancer centers.

Oncology Times - Latest Articles
MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors

The aim of this review is to summarize the major studies that have investigated the role of microRNAs as mediators of resistance to targeted therapies currently in use in GI neoplasms...

Single-Cell Sequencing, an Advanced Technology in Lung Cancer Research

This review summarizes lung cancer research using SCS and their research achievements.

OncoTargets and Therapy
Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy

The study demonstrates a significant improvement in overall survival with an estimated median OS of 10.9 months in the nivolumab arm compared with 8.4 months in the chemotherapy arm.

Prognostic Nomogram for Predicting Long-Term Cancer-Specific Survival in Patients With Lung Carcinoid Tumors

The current study establishes a nomogram model for predicting cancer-specific survival in patients with lung carcinoid tumors.

BMC Cancer
Medicaid Expansion Is Associated With Earlier Diagnosis of Gastric Cancer, Improved Survival

Medicaid expansion caused a decrease in uninsured patients and led to an earlier diagnosis of gastric cancer with an associated increase in 1-year survival.

The ASCO Post
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectom

The primary aim of the B-43 trial is to assess the efficacy of RT alone vs concurrent RT plus T in preventing recurrence of ipsilateral breast cancer in women with ductal carcinoma in situ.

Journal of Clinical Oncology
Genomic Landscape of Cutaneous Follicular Lymphomas Reveals 2 Subgroups With Clinically Predictive Molecular Features

Study investigators propose 3 criteria based on molecular features to predict cases of cutaneous FL with concurrent or future systemic involvement.

Blood Advances
Radiotherapy for Early and Advanced Stages Follicular Lymphoma

This study evaluates the results of radiotherapy for follicular lymphoma under different management scenarios.

Pembrolizumab for Non-Small Cell Lung Cancer Associated Brain Metastases

Dr Sarah B. Goldberg discusses the use of pembrolizumab for non-small cell lung cancer associated brain metastases.

Improving the Staging and Diagnosis of Patients With Stage III/IV Non-Small Cell Lung Cancer

Findings for Pathology and Pulmonary Medicine From a National Quality Survey, presented at the CAP 2020 Virtual Meeting.

Immunotherapy Trial Updates in NSCLC From ESMO 2020

Dr Roy Herbst discusses three abstracts presented at the ESMO 2020 virtual congress, including 5-year overall survival data from the KEYNOTE-024 study evaluating pembrolizumab versus CT in NSCLC...